Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Proteome Sciences ( (GB:PRM) ) has shared an update.
Proteome Sciences plc reported that all resolutions put to shareholders at its annual general meeting on 14 May 2026 were duly passed, including approval of the 2025 financial statements and the remuneration report. Investors also backed the reappointment of all board directors and the company’s auditors, Cooper Parry Group, signalling broad support for the existing leadership and governance structure.
Shareholders authorised the board to allot new equity securities and to disapply statutory pre-emption rights up to specified nominal limits, giving the company additional flexibility to raise capital if required. The strong endorsement across all resolutions reinforces management’s strategic latitude as Proteome Sciences pursues growth in contract proteomics services and biomarker discovery markets.
Spark’s Take on PRM Stock
According to Spark, TipRanks’ AI Analyst, PRM is a Neutral.
The score is primarily constrained by weak financial performance, driven by declining revenue, negative gross profit, sustained losses, and a stressed balance sheet with rising debt and deeply negative equity. Technicals are only mildly supportive (short-term rebound but still below the 200-day average with negative MACD), while valuation is hindered by ongoing losses (negative P/E) and no dividend data.
To see Spark’s full report on PRM stock, click here.
More about Proteome Sciences
Proteome Sciences plc is a specialist contract research provider focused on proteomics services that support drug discovery, development and biomarker identification for the life sciences sector. The company uses proprietary mass-spectrometry workflows, including SysQuant, TMT MS2, TMTcalibrator and chemoproteomics techniques, to analyse tissues, cells and body fluids and to develop targeted assays where standard ELISA tests are unavailable.
Average Trading Volume: 261,362
Technical Sentiment Signal: Sell
Current Market Cap: £6.14M
See more data about PRM stock on TipRanks’ Stock Analysis page.